PRMT4 promotes hepatocellular carcinoma progression by activating AKT/mTOR signaling and indicates poor prognosis: Erratum

Detalles Bibliográficos
Autores principales: Du, Peng, Luo, Kaifeng, Li, Guoyong, Zhu, Jisheng, Xiao, Qi, Li, Yong, Zhang, Xingjian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2022
Materias:
Erratum
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8964328/
https://www.ncbi.nlm.nih.gov/pubmed/35370468
http://dx.doi.org/10.7150/ijms.71614

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8964328/
https://www.ncbi.nlm.nih.gov/pubmed/35370468
http://dx.doi.org/10.7150/ijms.71614

Ejemplares similares